943994-61-4

Basic information

• Product Name: ethyl [(6-bromo-4-methyl-2-nitropyridin-3-yl)oxy]acetate
• CAS NO: 943994-61-4
• Molecular Weight: 319.112
• Mol File: 943994-61-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: ethyl [(6-bromo-4-methyl-2-nitropyridin-3-yl)oxy]acetate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl [(6-bromo-4-methyl-2-nitropyridin-3-yl)oxy]acetate(943994-61-4)
• EPA Substance Registry System: ethyl [(6-bromo-4-methyl-2-nitropyridin-3-yl)oxy]acetate(943994-61-4)

Safety Data

• Hazardous Substances Data: 943994-61-4(Hazardous Substances Data)

Upstream product

• 1303587-93-0 6-bromo-4-methyl-2-nitropyridin-3-ol 
• 105-36-2 ethyl bromoacetate 
• 1006-96-8 4-methylpyridin-3-yl acetate 
• 108-89-4 picoline 
• 1303587-92-9 3-acetoxy-4-methylpyridine-1-oxide 
• 1121-19-3 4-methylpyridin-3-ol 
• 15128-89-9 2-nitro-3-hydroxy-4-methylpyridine 
• 1003-67-4 4-methylpyridine-1-oxide 

Downstream Products

• 1303587-95-2 8-methyl-6-(3-(trifluoromethyl)phenyl)-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine 
• 1303585-26-3 8-methyl-N-(4-methylthiazol-2-yl)-6-(3-(trifluoromethyl)phenyl)-2H-pyrido[3,2-b][1,4]oxazine-4(3H)-carboxamide 

Relevant articles and documents

Structure activity relationship of pyridoxazinone substituted RHS analogs of oxabicyclooctane-linked 1,5-naphthyridinyl novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-6)

Abstract Oxabicyclooctane linked 1,5-naphthyridinyl-pyridoxazinones are novel broad-spectrum bacterial topoisomerase inhibitors (NBTIs) targeting bacterial DNA gyrase and topoisomerase IV at a site different than quinolones. Due to lack of cross-resistance to known antibiotics they present excellent opportunity to combat drug-resistant bacteria. A structure activity relationship of the pyridoxazinone moiety is described in this Letter. Chemical synthesis and activities of NBTIs with substitutions at C-3, C-4 and C-7 of the pyridoxazinone moiety with halogens, alkyl groups and methoxy group has been described. In addition, substitutions of the linker NH proton and its transformation into amide analogs of AM-8085 and AM-8191 have been reported. Fluoro, chloro, and methyl groups at C-3 of the pyridoxazinone moiety retained the potency and spectrum. In addition, a C-3 fluoro analog showed 4-fold better oral efficacy (ED50 3.9 mg/kg) as compared to the parent AM-8085 in a murine bacteremia model of infection of Staphylococcus aureus. Even modest polarity (e.g., methoxy) is not tolerated at C-3 of the pyridoxazinone unit. The basicity and NH group of the linker is important for the activity when CH2 is at the linker position-8. However, amides (with linker position-8 ketone) with a position-7 NH or N-methyl group retained potency and spectrum suggesting that neither basicity nor hydrogen-donor properties of the linker amide NH is essential for the activity. This would suggest likely an altered binding mode of the linker position-7,8 amide containing compounds. The amides showed highly improved hERG (functional IC50 >30 μM) profile.

FUSED HETEROCYCLIC COMPOUND AND USE THEREOF

The present invention relates to wherein each symbol is as defined in the specification. The compound has a superior mineral corticoidreceptorantagonistic action and is useful as an agent for the prophylaxis or treatment of hypertension, cardiac failure and the like, a compound having a fused heterocycle, or a prodrug thereof, or a salt thereof; and an agent for the prophylaxis or treatment of hypertension, cardiac failure and the like.